This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
Stocks · News reference
Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.